等待开盘 08-24 09:30:00 美东时间
0.000
0.00%
Lipocine(LPCN)2026年第二季度营收19.0万美元,同比下降约69.5%;净亏损扩大至262.3万美元,稀释每股亏损收窄至0.32美元,LPCN 1154三期主要终点未达标。
08-05 07:13
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $190.099 thousand whi...
08-04 18:19
Lipocine ( ($LPCN) ) has provided an announcement. On August 3, 2026, Lipocine ...
08-03 21:57
Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno, PhD, Vice
05-19 20:03
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effectiv...
05-18 20:00
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the
05-08 04:39
An update from Lipocine ( ($LPCN) ) is now available. On April 16, 2026, Lipoci...
04-22 04:46
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.
04-06 21:09
HC Wainwright & Co. analyst Yi Chen downgrades Lipocine (NASDAQ:LPCN) from Buy to Neutral.
04-06 20:06